logo

For the Inventor, By the Inventor

Antony, France

Stallergenes


USPTO Granted Patents = 13

% Expired Patents = 15.4



Trademarks = 4

Forward Citations = 7

Loading Chart...
Loading Chart...

25 inventors (with patents filed for the assignee):

goldMedal Philippe Moingeon (12 out of 14 patents)

silverMedal Emmanuel Nony (6 out of 29 patents)

bronzeMedal Laurent Mascarell (4 out of 5 patents)

4.  Véronique Bodo (4 out of 4 patents)

5.  Julien Bouley (4 out of 4 patents)

6.  Thierry Batard (3 out of 5 patents)

7.  Laurence Van Overtvelt (3 out of 3 patents)

8.  Alain Razafindratsita (3 out of 3 patents)

9.  Bertrand Villet (2 out of 2 patents)

10.  Vincent Lombardi (2 out of 2 patents)

11.  Claire Gueguen (2 out of 2 patents)

12.  Sophie Tourdot (2 out of 2 patents)

13.  Aline Zimmer (2 out of 3 patents)

14.  Noémie Caillot (1 out of 2 patents)

15.  Hélène Moussu (1 out of 1 patent)


13 patents:

1. 11028441 - IL-10 as a predictive biomarker of responsiveness to house dust mite allergen immunotherapy (2021-06-08),
2. 11027010 - Reduction of in vitro genotoxicity of pollen extracts by removal of flavonoids (2021-06-08),
3. 11015221 - Markers of immune response (2021-05-25),
4. 10884002 - Sialylated fetuin-A as a marker of immunotherapy efficacy (2021-01-05),
5. 10610586 - Compositions for antigen-specific induction of tolerance (2020-04-07),
6. 10190166 - Methods for identifying dendritic cell subsets, for determining if a patient is developing a regulatory or an effector immune response, and for determining response to immunotherapy (2019-01-29),
7. 10101341 - Biomarkers of immunotherapy efficacy (2018-10-16),
8. 9868770 - Recombinant Der P 2 expressed in Pichia Pastoris as a 'natural-like' allergen for immunotherapy and diagnostic purposes (2018-01-16),
9. 9822185 - Use of IGG1 immunoglobulins and/or ligands of the CD32 receptor for treating inflammatory diseases and incidents via the mucosa (2017-11-21),
10. 9795644 - Reduction of in vitro genotoxicity of pollen extracts by removal of flavonoids (2017-10-24),
11. 9555102 - Compositions for antigen-specific induction of tolerance (2017-01-31),
12. 9480748 - Mucoadhesive particulate formulation for inducing antigen-specific immune tolerance (2016-11-01),
13. 7285650 - [object Object] (2007-10-23),
Company Overview
Stallergenes is a biopharmaceutical company based in Antony, France, specializing in the development and manufacturing of allergen immunotherapy products. The organization focuses on innovative treatments for allergic diseases, particularly allergic rhinitis and asthma, utilizing advanced research in immunology and biotechnology. With a commitment to improving patient outcomes, Stallergenes aims to provide effective solutions that enhance the quality of life for individuals affected by allergies across various global markets.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Stallergenes USPTO Patent Assignee Logo
13 Patents

#7 in Antony

#1,398 in France

#44,988 in the World

Antony, FR
Antony, France

Stallergenes

Forward Citations = 7

25 inventors:

goldMedal Philippe Moingeon (12 out of 14 patents)

silverMedal Emmanuel Nony (6 out of 29 patents)

bronzeMedal Laurent Mascarell (4 out of 5 patents)

4.  Véronique Bodo (4 out of 4 patents)

5.  Julien Bouley (4 out of 4 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Stallergenes. Retrieved from https://idiyas.com/company/stallergenes

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…